Fette Compacting introduced its next-generation platform of tableting equipment with the F10i for small batches.
courtesy of Fette Compacting
Fette Compacting introduced its next-generation platform of i-series tableting equipment with the F10i for small batches. The new i Series retains and improves upon the efficiency of the existing i Series. The F10i is a single rotary press for small batches, with optional containment for highly active substances. Producers can adapt the tablet press to different requirements using a handling arm to support turret changes and a mechanical, manual turret clamping system.
The new series supports production with highly potent ingredients. The press-room design has been optimized for cleaning, and approximately half of all enclosure parts have been removed, which reduces the surface of the enclosure parts to be cleaned by approximately 70%. The machine is also dust-tight to minimize cleaning efforts and the risk of cross-contamination.
The press has technical connectivity and can be integrated via plug-and-play and open interfaces for connections to the Internet of things and a manufacturing execution system. Server-based, real-time monitoring allows the user to monitor production processes using mobile devices. A radio-frequency identification (RFID) option uses a contactless transceiver system to automatically identify process components so that they can be compared against preset recipes. This RFID system increases process reliability and avoids tooling errors.
A human machine interface supports the user in the form of intuitive control, monitoring, and documentation of the machine and process equipment via a terminal. Tactile feedback, which generates a vibration and a sound when the operating keys are touched, provides added certainty when making entries. A workflow operation assistant in the software supports the user to implement workflows safely and without error.
Source: Fette
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.